ASCO is now accepting abstracts to be considered for presentation or publication at the 46th Annual Meeting in Chicago, Illinois. This year’s Meeting will focus on Advancing Quality through Innovation and will provide an opportunity to discuss the latest innovations in research, quality, practice, and technology in cancer. ASCO encourages the submission of abstracts of 300-350 words in several areas. Innovations in research, which focus on new therapies to prevent, detect, and manage cancer, and innovations in quality, which highlight methods to improve care, mitigate disparities, ensure access to treatments, and maintain an adequate workforce for future patients will be two strong areas of focus. In addition, abstracts related to innovations in technology—the development of new and novel technologies to enable the entire oncology practice to operate more efficiently—also are encouraged.
| |
Call for Abstracts Website
Visit www.asco.org/cfa for quick links to the Abstract Submitter and to downloadable disclosure forms, as well as for detailed information about policies, guidelines, and frequently asked questions. |
|
ASCO has created a new Call for Abstracts website to provide authors with detailed information regarding changes to the submission process, submission requirements, Annual Meeting abstract policies, and the selection process. Visit
www.asco.org/cfa for quick links to the Abstract Submitter, Coauthor Disclosure Forms, Topic Categories, Biostatistical Guidelines, and Frequently Asked Questions.
All abstracts must be submitted through the official Abstract Submitter program at
www.asco.org/cfa by January 12, 2010, 11:59 PM Eastern Standard Time (EST).
Abstract Submission: Changes in 2010
As you prepare to submit your abstract, please keep in the mind the following changes to the 2010 abstract submission process:
- ASCO has a new electronic abstract submission system. Feedback is welcome and can be sent to abstracts@asco.org.
- A $60 administrative fee, payable at the time of submission, will be associated with all abstract submissions.
- E-mail addresses are now required for all Coauthors, as well as for the First Author. A search feature will be provided for ASCO member e-mail addresses. Please note that any changes to member information must be completed through the member profile on ASCO.org.
- First Authors of registered clinical trials will be asked to enter the name of the clinical trial registry and the trial registration number.
- A separate Coauthor Disclosure Form has been created for abstracts that report on clinical trials. Coauthor Disclosure Forms can be downloaded at www.asco.org/cfa.
- Late-breaking Abstract status has been expanded to include randomized phase II trials. For more detailed information on Late-breaking Abstracts, visit www.asco.org/cfa.
New Poster Session
The 2010 Annual Meeting will include the Trials in Progress Poster Session, designed exclusively to facilitate awareness of and dialogue about open, ongoing clinical trials. This session will encourage discussions of new clinical research and the exchange of ideas on clinical trial design.
Abstracts submitted to the Trials in Progress Poster Session should not include results. These abstracts will not count as the authors one allowed submission. The administrative fee will apply to this abstract category, and sponsorship must be attained from an ASCO Active or Active-Junior member, if the author is not an ASCO member. All conflict of interest policies apply. No CME credit will be offered for this session.
Changes to the Conflict of Interest Disclosure Process
If the First Author is employed by a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) and the abstract is selected for presentation in an oral abstract session, an alternate presenter who does not have a relevant employment relationship must be named.
Clinical trial abstracts that do not identify a principal investigator will be asked to answer additional questions.
